Healthcare
Nutriband Inc.(NTRB)
Live Price
Offline$2.90
-5.23% today
Window Change
-10.89%
Window
May 29, 2026 โ Jun 22, 2026
- Market Cap
- $50.00M
- Revenue Growth
- -4.8%
- EPS Growth
- -160.6%
- Dividend Yield
- 0.0%
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 16 bars ยท May 29, 2026 โ Jun 22, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Nutriband Inc. (NTRB) is a Healthcare stock with a market cap of $50.00M and listed on NASDAQ. The stock last traded around $2.90 and down 10.9% across the available one-year price window (May 29, 2026 โ Jun 22, 2026). Baseline metrics include revenue growth of -4.8%, EPS growth of -160.6%, a dividend yield of 0.0%. What stands out right now is revenue -4.8%, EPS -160.6%, free cash flow -8.8% with operating margin -408.4% and ROIC -120.1%. Valuation already assumes a fairly strong business story at price/sales 23.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines NTRB price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-4.8% vs +7.6% peer median
Operating Margin
Below sector median
-408.4% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 28, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -4.8% and EPS is at -160.6%, with operating margin around -408.4%.
Benchmark Edge
NTRB vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
NTRB
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
NTRB Max Drawdown
-18.99%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for NTRB and SPY.
Company Overview
Nutriband Inc.
NASDAQ Capital Market
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
- Leadership
- Gareth Sheridan
- IPO Date
- Oct 1, 2021
- Employees
- 13
- Street Address
- 121 South Orange Avenue
- Mailing
- Orlando, FL, 32801
- Region
- Orlando, FL, US
- Reporting Currency
- USD
- Investor Line
- 407 377 6695
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 23.0
- Price/Book
- 7.0
Growth
- Revenue
- -4.8%
- EPS
- -160.6%
- Free Cash Flow
- -8.8%
Profitability
- Gross Margin
- 24.9%
- Operating Margin
- -408.4%
- Net Margin
- -404.1%
- ROE
- -118.3%
- ROIC
- -120.1%
Balance Sheet
- Debt/Equity
- 0.03
- Current Ratio
- 6.36
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.